Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non-Small Cell Lung Cancers

First-line afatinib appears cost-effective compared with gefitinib for patients with EGFR mutation-positive NSCLCs.